NASDAQ:JANX - Get Free Report )'s stock price dropped 11.5% during mid-day trading on Wednesday . The stock traded as low as $51.63 and last traded at $54.45. Approximately 664,579 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 765,020 shares. The stock had previously closed at $61.50.
Get Janux Therapeutics alerts:
Sign Up
Analysts Set New Price Targets JANX has been the subject of several research reports. Cantor Fitzgerald assumed coverage on shares of Janux Therapeutics in a research note on Wednesday, March 20th. They set an "overweight" rating and a $100.00 price objective for the company. Jonestrading began coverage on shares of Janux Therapeutics in a report on Tuesday, April 16th. They issued a "buy" rating and a $70.00 price target on the stock. BTIG Research assumed coverage on Janux Therapeutics in a report on Thursday, March 21st. They issued a "buy" rating and a $62.00 price objective for the company. Wedbush raised their target price on Janux Therapeutics from $53.00 to $74.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research note on Tuesday, February 27th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and a consensus target price of $64.83.
Read Our Latest Stock Report on Janux Therapeutics
Janux Therapeutics Price Performance The company has a market capitalization of $2.87 billion, a PE ratio of -39.96 and a beta of 3.87. The stock has a 50-day simple moving average of $45.03 and a 200 day simple moving average of $22.15.
Janux Therapeutics (NASDAQ:JANX - Get Free Report ) last posted its earnings results on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.12. The firm had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.98 million. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. As a group, research analysts predict that Janux Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.
Institutional Investors Weigh In On Janux Therapeutics A number of institutional investors have recently bought and sold shares of the stock. FMR LLC grew its stake in shares of Janux Therapeutics by 25.5% during the 3rd quarter. FMR LLC now owns 6,351,322 shares of the company's stock valued at $64,021,000 after buying an additional 1,288,526 shares during the period. RA Capital Management L.P. raised its position in Janux Therapeutics by 5.7% in the third quarter. RA Capital Management L.P. now owns 9,165,652 shares of the company's stock valued at $92,390,000 after purchasing an additional 495,008 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of Janux Therapeutics by 27.8% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company's stock worth $11,592,000 after purchasing an additional 250,000 shares in the last quarter. Cerity Partners LLC purchased a new stake in shares of Janux Therapeutics in the fourth quarter worth about $654,000. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of Janux Therapeutics in the first quarter worth about $1,969,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.
About Janux Therapeutics (
Get Free Report )
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Further Reading Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
